KBC

MICLEDI Microdisplays BV specializes in designing and manufacturing micro light-emitting diode (microLED) display chips tailored for augmented reality (AR) glasses. Based in Leuven, Belgium, the company operates as a fabless developer, focusing on advanced technology that integrates III/V materials processing, 3D integration, and 300mm silicon-based processing. MICLEDI's proprietary application-specific integrated circuit (ASIC) enables the production of compact, monolithic AR displays that deliver high image quality and enhanced power efficiency. By providing microLED display modules on wafers, MICLEDI serves the semiconductor industry, contributing to the advancement of AR technology.

ArtiQ is an innovative spin-off from the University of Leuven, founded in early 2019 by a team with extensive experience in respiratory medicine, medical devices, and artificial intelligence. The company focuses on developing AI-backed software to support medical professionals in diagnosing, treating, and monitoring patients with lung diseases. By automating the interpretation of pulmonary function tests, ArtiQ's technology enhances the accuracy and efficiency of the diagnostic process, facilitating the early detection of disease patterns. This approach not only aids healthcare practitioners in making informed decisions but also aims to improve the overall environment for lung disease diagnostics, ultimately benefiting patients and the healthcare system. ArtiQ aspires to be a trusted partner for medical practitioners in addressing respiratory issues.

UBB Interlease is a Bulgarian lease company part of the Belgian banking and insurance group KBC. The activities of Interlease are targeted towards increasing the competitiveness and improving the market positions of the Bulgarian enterprises both domestically and abroad. Interlease finances the acquisition of high-quality equipment, transportation vehicles, cars and office equipment. The company provides its customers with professional service after delivery of the asset, based on effective internet and mobile technologies.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.

Aristo Music NV develops selection and distribution techniques and technologies for digital music and provides music related services. The company also develops various Internet applications, which include a Web radio that consists of a musical database. It serves catering, retail, business, leisure, and government markets. The company is based in Heverlee, Belgium.

Okapi Sciences NV is a Belgium-based company focused on developing antiviral therapeutics for pets and livestock. It operates a proprietary platform dedicated to creating innovative treatments for significant viral diseases, with five candidates currently in clinical or development stages. The company specializes in addressing viral infections affecting pets, particularly through its work on feline herpes and feline immunodeficiency virus. Okapi Sciences is committed to advancing its pipeline of antiviral drugs while fostering strong relationships with academic institutions to enhance its research capabilities and technological advancements in veterinary medicine.

Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company's lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient's refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.